CONMED reported fourth-quarter fiscal 2025 earnings per share of $1.12 on non‐GAAP basis, surpassing analysts’ consensus of $0.98. Total revenue reached $337 million, beating the Street estimate of $329 million and representing a 7% increase year-over-year. Gross margin expanded to 64.5%, up from 62.8% in the year-ago quarter, driven by improved manufacturing efficiencies and a favorable product mix.

Sales in the surgical products segment climbed 8% to $218 million, fueled by strong demand for advanced laparoscopy devices and the rollout of a next-generation orthopedic power tool system. International revenue rose 10% year-over-year, accounting for 29% of total company sales, as distributors in Europe and Asia completed new stocking orders ahead of upcoming regulatory changes.

Management set fiscal 2026 revenue guidance between $1.38 billion and $1.40 billion, implying mid‐single‐digit growth. Non‐GAAP earnings per share are projected in the range of $4.20 to $4.30. The board authorized a new $100 million share repurchase program, building on $75 million returned to shareholders in the previous 12 months, while maintaining full-year R&D spending near 6.5% of revenue.